Can plasma DNA monitoring be employed in personalized chemotherapy for patients with advanced lung cancer?

Biomedicine and Pharmacotherapy

Volumn 66, Issue 2, 2012, Pages 131-137

  Pan, Shiyang ^a   Xia, Wenying ^a   Ding, Qingqing ^a   Shu, Yongqian ^a   Xu, Ting ^a   Geng, Yan ^a   Lu, Yachun ^a   Chen, Dan ^a   Xu, Jian ^a   Wang, Fang ^a   Zhao, Chun ^a   Huang, Peijun ^a   Huang, Puwen ^a   Shen, Hongbing ^b   Hu, Zhibin ^b   Lu, Shan ^c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Advanced lung cancer; Personalized chemotherapy; Plasma DNA

Indexed keywords

CISPLATIN; DNA; DOCETAXEL; GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; FEMALE; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84862826619     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2011.11.022     Document Type: Article

References (62)

1. Jemal A., Siegel R., Ward E., Hao Y.P., Xu J.Q., Murray T., et al. Cancer statistics. CA Cancer J Clin 2008, 58:71-96.
2. Patel N., Adatia R., Mellemgaard A., Jack R., Møller H. Variation in the use of chemotherapy in lung cancer. Br J Cancer 2007, 96:886-890.
3. Lyengar P., Tsao M.S. Clinical relevance of molecular markers in lung cancer. Surg Oncol 2002, 11:167-179.
4. Cho W.C. Potentially useful biomarkers for the diagnosis, treatment and prognosis of lung cancer. Biomed Pharmacother 2007, 61:515-519.
5. Fournie G.J., Courtin J.P., Laval F., Chale J.J., Pourrat J.P., Pujazon M.C., et al. Plasma DNA as a marker of cancerous cell death. Investigations in patients suffering from lung cancer and in nude mice bearing human tumors. Cancer Lett 1995, 91:221-227.
6. Holdenrieder S., Stieber P., Forg T., Kukl M., Schulz L., Busch M., et al. Apoptosis in serum of patients with solid tumors. Anticancer Res 1999, 19:2721-2724.
7. Stroun M., Lyautey J., Lederrey C., Olson-Sand A., Anker P. About the possible origin and mechanism of circulating DNA apoptosis and active DNA release. Clin Chim Acta 2001, 313:139-142.
8. Ziegler A., Zangemeister-Wittke U., Stahel R.A., Circulating D.N.A. A new diagnostic gold mine?. Cancer Treat Rev 2002, 28:255-271.
9. Sozzi G., Conte D., Leon M., Cirincione R., Roz L., Ratcliffe C., et al. Quantification of free circulating DNA as a diagnostic marker in lung cancer. J Clin Oncol 2003, 21:3902-3908.
10. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
11. Fleischhacker M., Schmidt B. Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007, 1775:181-232.
12. Yoon K.A., Park S., Lee S.H., Kim J.H., Lee J.S. Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls. J Mol Diagn 2009, 11:182-185.
13. Chan K.C., Lo Y.M. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer 2007, 96:681-685.
14. Mouliere F., Robert B., Arnau Peyrotte E., Del Rio M., Ychou M., Molina F., et al. High fragmentation characterizes tumour-derived circulating DNA. Plos One 2011, 6(9):e23418.
15. Capizzi E., Gabusi E., Grigioni A.D., De Iaco P., Rosati M., Zamagni C., et al. Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer. Diagn Mol Pathol 2008, 17:34-38.
16. Kamat A.A., Bischoff F.Z., Dang D., Baldwin M.F., Han L.Y., Lin Y.G., et al. Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma. Cancer Biol Ther 2006, 5:1369-1374.
17. Van der Auwera I., Elst H.J., Van Laere S.J., Maes H., Huget P., van Dam P., et al. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009, 100:1277-1286.
18. Anker P., Mulcahy H., Chen X.Q., Stroun M. Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev 1999, 18:65-73.
19. Pathak A.K., Bhutani M., Kumar S., Mohan A., Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006, 52:1833-1842.
20. Gormally E., Caboux E., Vineis P., Hainaut P. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007, 635:105-117.
21. Holdenrieder S., Stieber P., von Pawel J., Raith H., Nagel D., Feldmann K., et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small-cell lung cancer. Lung Cancer 2004, 10:5981-5987.
22. Fiegl H., Millinger S., Mueller-Holzner E., Christian Marth, Ensinger C., Berger A., et al. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005, 65:1141-1145.
23. Frattini M., Gallino G., Signoroni S., Balestra D., Battaglia L., Sozzi G., et al. Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Ann NY Acad Sci 2006, 1075:185-190.
24. Schwarzenbach H., Stoehlmacher J., Pantel K., Goekkurt E. Detection and monitoring of cell free DNA in blood of patients with colorectal cancer. Ann NY Acad Sci 2008, 1137:190-196.
25. Postma C., Koopman M., Buffart T.E., Eijk P.P., Carvalho B., Peters G.J., et al. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol 2009, 20:1048-1056.
26. Cheng C., Omura-Minamisawa M., Kang Y., Hara T., Koike I., Inoue T. Quantification of circulating cell-free DNA in the plasma of cancer patients during radiation therapy. Cancer Sci 2009, 10:303-309.
27. Therasse P., Arbuck S.G., Eisenhauer E.A., Jantien Wanders, Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
28. Lo Y.M.D., Tein M.S.C., Lau T.K., Haines C.J., Leung T.N., Poon P.M.K., et al. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for non-invasive prenatal diagnosis. Am J Hum Genet 1998, 62:768-775.
29. Shepherd F.A. Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time. J Clin Oncol 2008, 26:2426-2427.
30. Chua W., Goldstein D., Lee C.K., Dhillon H., Michael M., Mitchell P., et al. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer 2009, 101:998-1004.
31. Vitucci M., Hayes D.N., Miller C.R. Gene expression profiling of gliomas: merging genomic and histopathological classification for personalised therapy. Br J Cancer 2010, 104:545-553.
32. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefi{ligature}tinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
33. Gamelin E., Delva R., Jacob J., Merrouche Y., Raoul J.L., Pezet D., et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with etastatic colorectal cancer. J Clin Oncol 2008, 26:2099-2105.
34. Gronlund B., Høgdall C., Hilden J., Engelholm S.A., Høgdall E.V.S., Hansen H.H. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?. J Clin Oncol 2004, 22:4051-4058.
35. Duffy M.J. Role of tumor markers in patients with solid cancers: a critical review. Eur J Inter Med 2007, 18:175-184.
36. Pan S.Y., Xie E.F., Shu Y.Q., Gao L., Zhang L.X., Chen D., et al. Methylation quantification of adenomatous polyposis coli (APC) gene promoter in plasma of lung cancer patients. Ai Zheng 2009, 28:384-389.
37. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage 1 lung cancer. N Engl J Med 2008, 358:1118-1128.
38. Zhibin Hu, Jiaping Chen, Tian Tian, Xiaoyi Zhou, Haiyong Gu, Lin Xu, et al. Genetic variants of miRNA sequences and non-small-cell lung cancer survival. J Clin Invest 2008, 118:2600-2608.
39. Pan S., Zhang L., Gao L., Gu B., Wang F., Xu J., et al. The property of methylated APC gene promoter and its influence on lung cancer cell line. Biomed Pharmacother 2009, 63:463-468.
40. Ding QQ, Mu Y, Pan SY, Shu YQ, Zhang SJ, Zhang BF, et al. Plasma DNA methylation analysis in predicting short-term recurrence of surgical patients with non-small-cell lung cancer (NSCLC). In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Netherlands: Springer Science+Business Media B.V; 2011, p.47-55.
41. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
42. Deligezer U., Eralp Y., Akisik E.E., Akisik E.Z., Saip P., Topuz E., et al. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy. Clin Chem Laboratory Med 2008, 46:311-317.
43. Lo Y.M.D., Chan A.T., Chan L.Y., Leung S.F., Lam C.W., Huang D.P., et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000, 60:6878-6881.
44. Rosell R., Cecere F., Santarpia M., Reguart N., Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006, 6:323-331.
45. Papadaki C., Tsaroucha E., Kaklamanis L., Lagoudaki E., Trypaki M., Tryfonidis K., et al. Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer. Br J Cancer 2010, 104:316-323.
46. Gao W., Yu Y., Cao H., Shen H., Li X., Pan S., et al. Deregulated expression of miR-21, miR-143 and miR-181a in non-small-cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010, 64:399-408.
47. Galeazzi M., Morozzi G., Piccini M., Chen J., Bellisai F., Fineschi S., et al. Dosage and characterization of circulating DNA: present usage and possible applications in systemic autoimmune disorders. Autoimmun Rev 2003, 2:50-55.
48. Steinman C.R. Circulating DNA in polyarteritis nodosa and related syndromes. Arthritis Rheum 1982, 25:1425-1430.
49. Laktionov P.P., Tamkovich S.N., Rykova E.Y., Bryzgunova O.E., Starikov A.V., Kuznetsova N.P., et al. Extracellular circulating nucleic acids in human plasma in health and disease. Nucleosides Nucleotides Nucleic Acids 2004, 23:879-883.
50. Jahr S., Hentze H., Englisch S., Hardt D., Fackelmayer F.O., Hesch R.D., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
51. Lo Y.M.D., Zhang J., Leung T.N., Lau T.K., Chang A.M., Hjelm N.M. Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 1999, 64:218-224.
52. Diehl F., Schmidt F., Choti M.A., Romans K., Goodman S., Li M., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
53. Kuroi K., Tanaka C., Toi M. Clinical significance of plasma nucleosomes levels in cancer patients. Int J Oncol 2001, 19:143-148.
54. Trejo-Becerril C., Oñate-Ocaña L.F., Taja-Chayeb L., Vanoye-Carlo A., Cetina L., Duenas-Gonzalez A. Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance. BMC cancer 2005, 5:65.
55. Sozzi G., Conte D., Mariani L., Vullo S.L., Roz L., Lombardo C., et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001, 61:4675-4678.
56. Beau-Faller M., Gaub M.P., Schneider A., Ducrocq X., Massard G., Gasser B., et al. Plasma DNA microsatellite panel as sensitive and tumor-specifi{ligature}c marker in lung cancer patients. Int J Cancer 2003, 105:361-370.
57. Ludovini V., Pistola L., Gregorc V., Floriani I., Rulli E., Piattoni S., et al. Plasma DNA microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small-cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology. J Thorac Oncol 2008, 3:365-373.
58. Van der Drift M.A., Hol B.E., Klaassen C.H., Prinsen C.F., van Aarssen Y.A., Donders R., et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small-cell lung cancer. Lung Cancer 2010, 68:283-287.
59. Gautschi O., Bigosch C., Huegli B., Jermann M., Marx A., Chassé E., et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004, 22:4157-4164.
60. Sozzi G., Roz L., Conte D., Mariani L., Andriani F., Vullo S.L., et al. Plasma DNA quantifi{ligature}cation in lung cancer computed tomography screening: fi{ligature}ve-year results of a prospective study. Am J Respir Crit Care Med 2009, 179:69-74.
61. Sozzi G., Roz L., Conte D., Mariani L., Andriani F., Verderio P., et al. Effects of prolonged storage of whole plasma or isolated plasma DNA on the results of circulating DNA quantifi{ligature}cation assays. J Natl Cancer Inst 2005, 97:1848-1850.
62. Chen D, Pan SY, Zhang SJ, Huang PJ, Xia WY, Xie EF, et al. The clinical significance of plasma DNA quantification for quake trauma patients. In: Gahan PB, editor. Circulating nucleic acids in plasma and serum. Netherlands: Springer Science+Business Media B.V; 2011, p.171-82.